Cited 11 times in
Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 배재현 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이용호 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2019-12-18T00:53:05Z | - |
dc.date.available | 2019-12-18T00:53:05Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173259 | - |
dc.description.abstract | INTRODUCTION: Comparisons of the glycemic durability between thiazolidinediones (TZDs) and dipeptidyl peptidase-4 (DPP-4) inhibitors remain insufficient. This study aimed to find clues for the differences in glycemic durability between TZDs and DPP-4 inhibitors by comparing the insulin resistance and β-cell function among patients using these agents. METHODS: A total of 241 patients with type 2 diabetes mellitus (T2DM) treated with either pioglitazone (a TZD) or DPP-4 inhibitors as combination therapy with metformin for at least 1 year were analyzed. A propensity score based on the patients' baseline characteristics and glycated hemoglobin (HbA1c) was used to match them. Indices for insulin resistance and secretory function of β-cells, namely the homeostasis model assessment of insulin resistance (HOMA-IR) or β-cells (HOMA-β), were calculated and compared. Multiple regression analysis was performed to find the independent variables correlated with β-cell function or insulin resistance. RESULTS: Evaluation of the data from 168 matched patients with T2DM showed that TZD users had significantly better insulin sensitivity compared with DPP-4 inhibitor users (HOMA-IR 2.3 ± 1.9 vs. 3.5 ± 3.2, p = 0.003). Conversely, DPP-4 inhibitor users secreted more insulin than TZD users (HOMA-β 45.7 ± 31.6 vs. 61.4 ± 49.5, p = 0.016). Multiple linear regression analysis showed that these agents were independently associated with both insulin resistance and β-cell function. CONCLUSION: TZD users showed significantly better insulin sensitivity, whereas DPP-4 inhibitor users secreted more insulin from β-cells under similar glycemic control. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer Healthcare | - |
dc.relation.isPartOf | DIABETES THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jaehyun Bae | - |
dc.contributor.googleauthor | Gyuri Kim | - |
dc.contributor.googleauthor | Yong-Ho Lee | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.contributor.googleauthor | Bong-Soo Cha | - |
dc.identifier.doi | 10.1007/s13300-018-0541-y | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A01803 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J02908 | - |
dc.identifier.eissn | 1869-6953 | - |
dc.identifier.pmid | 30506494 | - |
dc.subject.keyword | Antidiabetic agents | - |
dc.subject.keyword | Dipeptidyl-peptidase 4 inhibitors | - |
dc.subject.keyword | Insulin resistance | - |
dc.subject.keyword | Thiazolidinedione | - |
dc.subject.keyword | β-Cell function | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | 강은석 | - |
dc.contributor.affiliatedAuthor | 배재현 | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.contributor.affiliatedAuthor | 이용호 | - |
dc.contributor.affiliatedAuthor | 차봉수 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 149 | - |
dc.citation.endPage | 158 | - |
dc.identifier.bibliographicCitation | DIABETES THERAPY, Vol.10(1) : 149-158, 2019 | - |
dc.identifier.rimsid | 64320 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.